ArticleFrontiers in behavioral neuroscience2026
Remote control of wildtype zebrafish optomotor response with a photoswitchable drug.
Article in Frontiers in behavioral neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Introduction: For animals to interact effectively with their environment, the brain must integrate sensory information and generate appropriate motor responses. Multiple neuronal circuits contribute to this process, and identifying their roles remains a central focus in neuroscience. In this context, photopharmacology provides light-controllable compounds that enable remote and spatially and temporally precise modulation of neuronal activity without requiring genetic modification. This approach minimizes off-target activation of unwanted brain regions while allowing reversible control of neural circuits. The recently developed photoswitchable compound Carbadiazocine has been shown to reversibly control neuronal firing across multiple species in a light-dependent manner. It modulates larval zebrafish locomotion and alleviates neuropathic pain in rodents in a reversible, light-induced manner. Given the established Methods: We focused on the optomotor response in zebrafish larvae and assessed its potential as a tool for circuit perturbation and behavioral analysis, for the first time combined with photopharmacology. We performed experiments in head-fixed and free-swimming larvae to assess their capacity to detect and follow optic flow, and to characterize swimming speed patterns and tail bout properties following administration of the two Carbadiazocine photoisomers. Results: In both paradigms, treatment with the pre-illuminated compound decreased accuracy in responding to optic flow (correct turning percentage dropping from ~95% to ~80% in head-fixed experiments and from ~65% to ~20% in free-swimming experiments). Speed analysis revealed more frequent and prolonged fast movements, with fewer slow movements, even without visual stimulation. Tail bout analysis showed increased 15-30 Hz bout frequencies, corresponding to irregular tail movements. These effects were absent with the dark-relaxed compound. Discussion: Together, these findings provide a foundation to probe neuronal circuits underlying behavior in diverse animal species using a dynamic range of photostimulation patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.